Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Protara Therapeutics, Inc.TARA · Entity 6203 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Protara Therapeutics, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2036-06-14 | Direct | 31,000 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 31,000 · Balance 31,000 F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Filing footnotes · ownership attribution and instrument terms
F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Avid Bioservices, Inc.
Report date February 05, 2025 · Filed February 07, 2025
Section 16 reporting ended · disclosed 2025-02-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-02-05 transaction · row 1
1 source rowRow 1 · 2025-02-05 · Disposition to issuer · Disposed 36,368 · Balance 0 F1: Represents shares of common stock that were disposed of at the effective time (the "Effective Time") of the merger (the "Merger") of Space Mergerco, Inc. ("Merger Sub") with and into Avid Bioservices, Inc. (the "Issuer") pursuant to the Agreement and Plan of Merger, dated as of November 6, 2024 (the "Merger Agreement"), by and among the Issuer, Space Finco, Inc., and Merger Sub. F2: At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive a cash payment per share of $12.50, without interest, subject to the terms and conditions of the Merger Agreement (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.67 · Expires 2027-11-27 | Direct | 49,305 |
Reported balance
After 2025-02-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-05 · Disposition to issuer · Disposed 75,000 · Balance 49,305 F3: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.22 · Expires 2025-12-14 | Direct | 29,705 |
Reported balance
After 2025-02-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-05 · Disposition to issuer · Disposed 19,600 · Balance 29,705 F3: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.72 · Expires 2027-12-14 | Direct | 0 |
Reported balance
After 2025-02-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-02-05 · Disposition to issuer · Disposed 10,030 · Balance 0 F3: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. |
| Stock Option right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.87 · Expires 2027-01-09 | Direct | 10,030 |
Reported balance
After 2025-02-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-05 · Disposition to issuer · Disposed 19,675 · Balance 10,030 F3: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2025-02-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-02-05 · Disposition to issuer · Disposed 8,147 · Balance 0 F5: Represents restricted stock units ("RSUs") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F6: At the Effective Time, each unvested RSU was cancelled and converted solely into the right to receive a cash payment of $12.50 per share of common stock subject to such unvested RSU, without interest, subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock that were disposed of at the effective time (the "Effective Time") of the merger (the "Merger") of Space Mergerco, Inc. ("Merger Sub") with and into Avid Bioservices, Inc. (the "Issuer") pursuant to the Agreement and Plan of Merger, dated as of November 6, 2024 (the "Merger Agreement"), by and among the Issuer, Space Finco, Inc., and Merger Sub.
F2: At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive a cash payment per share of $12.50, without interest, subject to the terms and conditions of the Merger Agreement (the "Merger Consideration").
F3: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub.
F4: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement.
F5: Represents restricted stock units ("RSUs") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub.
F6: At the Effective Time, each unvested RSU was cancelled and converted solely into the right to receive a cash payment of $12.50 per share of common stock subject to such unvested RSU, without interest, subject to the terms and conditions of the Merger Agreement.
CAMBREX CORP
Report date December 04, 2019 · Filed December 05, 2019
Section 16 reporting ended · disclosed 2019-12-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-12-04 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2019-12-04 · Exercise / conversion · Acquired 7,500 · Balance 39,925 Row 2 · 2019-12-04 · Exercise / conversion · Acquired 15,000 · Balance 54,925 Row 3 · 2019-12-04 · Exercise / conversion · Acquired 22,500 · Balance 77,425 Row 4 · 2019-12-04 · Exercise / conversion · Acquired 25,000 · Balance 102,425 Row 5 · 2019-12-04 · Exercise / conversion · Acquired 20,000 · Balance 122,425 Row 6 · 2019-12-04 · Grant · Acquired 43,500 · Balance 165,925 F1: Each Company restricted stock unit subject to performance-vesting conditions (each, a "Company PSU") that was outstanding immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00, multiplied by the total number of shares of Company Common Stock subject to such Company PSU, with any performance-based vesting conditions deemed achieved at the greater of (x) target levels of performance and (y) actual levels of performance, without pro-ration. Row 7 · 2019-12-04 · Sale · Disposed 165,925 · Balance 0 F2: Disposed of for $60.00 per share pursuant to the terms of that certain Agreement and Plan of Merger dated as of August 7, 2019, by and among Catalog Intermediate Inc. ("Parent"), Catalog Merger Sub ("Merger Sub"), each entities controlled by investment funds advised by Permira Advisors LLC, and the Company (the "Merger Agreement"). All terms capitalized but not defined shall have the respective meanings given to them in the Merger Agreement. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.81 | Direct | 0 |
Reported balance
After 2019-12-04 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-12-04 · Exercise / conversion · Acquired 7,500 · Balance 0 F3: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.36 | Direct | 0 |
Reported balance
After 2019-12-04 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-12-04 · Exercise / conversion · Acquired 15,000 · Balance 0 F3: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.65 | Direct | 0 |
Reported balance
After 2019-12-04 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-12-04 · Exercise / conversion · Acquired 22,500 · Balance 0 F3: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.64 | Direct | 0 |
Reported balance
After 2019-12-04 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-12-04 · Exercise / conversion · Acquired 25,000 · Balance 0 F3: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.61 | Direct | 0 |
Reported balance
After 2019-12-04 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-12-04 · Exercise / conversion · Acquired 20,000 · Balance 0 F3: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Company restricted stock unit subject to performance-vesting conditions (each, a "Company PSU") that was outstanding immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00, multiplied by the total number of shares of Company Common Stock subject to such Company PSU, with any performance-based vesting conditions deemed achieved at the greater of (x) target levels of performance and (y) actual levels of performance, without pro-ration.
F2: Disposed of for $60.00 per share pursuant to the terms of that certain Agreement and Plan of Merger dated as of August 7, 2019, by and among Catalog Intermediate Inc. ("Parent"), Catalog Merger Sub ("Merger Sub"), each entities controlled by investment funds advised by Permira Advisors LLC, and the Company (the "Merger Agreement"). All terms capitalized but not defined shall have the respective meanings given to them in the Merger Agreement.
F3: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2018 Filed May 9, 2018 16:24 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $16.91 | $0.00 |
DisclosureSEC source: 0001209191-18-028866 · doc4.xml · derivative · entry 9 SARGEN GREGORY · CIK 0001227835 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2020-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option representing a right to purchase 30,000 shares became exercisable in four equal installments beginning October 28, 2014, which was the first anniversary of the date on which the option was granted. Read SEC document |
| May 08, 2018 Filed May 9, 2018 16:24 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 33,933 | $49.63 | $1,683,938.70 |
DisclosureSEC source: 0001209191-18-028866 · doc4.xml · nonDerivative · entry 8 SARGEN GREGORY · CIK 0001227835 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.50 to $49.85 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 5 to this Form 4. Read SEC document |
| May 08, 2018 Filed May 9, 2018 16:24 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 10,565 | $49.05 | $518,213.25 |
DisclosureSEC source: 0001209191-18-028866 · doc4.xml · nonDerivative · entry 7 SARGEN GREGORY · CIK 0001227835 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,933 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.50 to $49.45 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 4 to this Form 4. Read SEC document |
| May 08, 2018 Filed May 9, 2018 16:24 UTC | CAMBREX CORP CBM · Entity 153359 | GrantCommon Stock | 7,500 | $40.65 | $304,875.00 |
DisclosureSEC source: 0001209191-18-028866 · doc4.xml · nonDerivative · entry 6 SARGEN GREGORY · CIK 0001227835 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,498 Read SEC document |
| May 08, 2018 Filed May 9, 2018 16:24 UTC | CAMBREX CORP CBM · Entity 153359 | GrantCommon Stock | 15,000 | $41.36 | $620,400.00 |
DisclosureSEC source: 0001209191-18-028866 · doc4.xml · nonDerivative · entry 5 SARGEN GREGORY · CIK 0001227835 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,998 Read SEC document |
| May 08, 2018 Filed May 9, 2018 16:24 UTC | CAMBREX CORP CBM · Entity 153359 | GrantCommon Stock | 7,500 | $17.81 | $133,575.00 |
DisclosureSEC source: 0001209191-18-028866 · doc4.xml · nonDerivative · entry 4 SARGEN GREGORY · CIK 0001227835 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,998 Read SEC document |
| May 08, 2018 Filed May 9, 2018 16:24 UTC | CAMBREX CORP CBM · Entity 153359 | GrantCommon Stock | 7,500 | $16.91 | $126,787.50 |
DisclosureSEC source: 0001209191-18-028866 · doc4.xml · nonDerivative · entry 3 SARGEN GREGORY · CIK 0001227835 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,498 Read SEC document |
| May 07, 2018 Filed May 9, 2018 16:24 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 23,002 | $49.46 | $1,137,720.32 |
DisclosureSEC source: 0001209191-18-028866 · doc4.xml · nonDerivative · entry 2 SARGEN GREGORY · CIK 0001227835 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,998 F2 · shares: Broker-assisted sale of which 14,805 shares were to cover the payment of withholding tax liability from the settlement of a performance share award. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.20 to $49.875 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4. Read SEC document |
| May 07, 2018 Filed May 9, 2018 16:24 UTC | CAMBREX CORP CBM · Entity 153359 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-028866 · doc4.xml · nonDerivative · entry 1 SARGEN GREGORY · CIK 0001227835 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: Pursuant to settlement of a performance share award. Read SEC document |
| November 27, 2017 Filed Nov 29, 2017 20:08 UTC | Avid Bioservices, Inc. PPHM · Entity 83494 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $4.67 | $0.00 |
DisclosureSEC source: 0001683168-17-003189 · sargen_frm4.xml · derivative · entry 1 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-11-27 F1 · derivative.exercise_date: This option vests in thirty-six (36) equal monthly installments over a three (3) year period beginning December 27, 2017. Read SEC document |
| October 30, 2017 Filed Nov 1, 2017 17:14 UTC | CAMBREX CORP CBM · Entity 153359 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $45.64 | $0.00 |
DisclosureSEC source: 0001437749-17-018054 · rdgdoc.xml · derivative · entry 1 SARGEN GREGORY · CIK 0001227835 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2024-10-30 F1 · derivative.exercise_date: The option representing a right to purchase a total of 25,000 shares becomes exercisable in four equal installments beginning October 30, 2018, which is the first anniversary of the date on which the option was granted. Read SEC document |
| February 07, 2017 Filed Feb 8, 2017 16:47 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 30,000 | $54.88 | $1,646,400.00 |
DisclosureSEC source: 0001437749-17-001931 · rdgdoc.xml · nonDerivative · entry 2 SARGEN GREGORY · CIK 0001227835 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F2 · shares: Broker-assisted sale of which 15,135 shares sold were to cover the payment of withholding tax liability arising from the settlement of performance share award F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.68 to $55.15 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4 Read SEC document |
| February 07, 2017 Filed Feb 8, 2017 16:47 UTC | CAMBREX CORP CBM · Entity 153359 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-001931 · rdgdoc.xml · nonDerivative · entry 1 SARGEN GREGORY · CIK 0001227835 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: Pursuant to settlement of a performance share award Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 21:22 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $17.81 | $0.00 |
DisclosureSEC source: 0001437749-16-042120 · rdgdoc.xml · derivative · entry 7 SARGEN GREGORY · CIK 0001227835 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 7,500 shares Expires 2021-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option representing a right to purchase 30,000 shares became exercisable in four equal installments beginning October 22, 2015, which was the first anniversary of the date on which the option was granted. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 21:22 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $16.91 | $0.00 |
DisclosureSEC source: 0001437749-16-042120 · rdgdoc.xml · derivative · entry 6 SARGEN GREGORY · CIK 0001227835 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2020-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option representing a right to purchase 30,000 shares became exercisable in four equal installments beginning October 28, 2014, which was the first anniversary of the date on which the option was granted. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 21:22 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $12.46 | $0.00 |
DisclosureSEC source: 0001437749-16-042120 · rdgdoc.xml · derivative · entry 5 SARGEN GREGORY · CIK 0001227835 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2019-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option representing a right to purchase 30,000 shares became exercisable in four equal installments beginning October 24, 2013, which was the first anniversary of the date on which the option was granted. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 21:22 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 22,500 | $52.02 | $1,170,450.00 |
DisclosureSEC source: 0001437749-16-042120 · rdgdoc.xml · nonDerivative · entry 4 SARGEN GREGORY · CIK 0001227835 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.85 to $52.35 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 1 to this Form 4. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 21:22 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 7,500 | $17.81 | $133,575.00 |
DisclosureSEC source: 0001437749-16-042120 · rdgdoc.xml · nonDerivative · entry 3 SARGEN GREGORY · CIK 0001227835 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 21:22 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 7,500 | $16.91 | $126,825.00 |
DisclosureSEC source: 0001437749-16-042120 · rdgdoc.xml · nonDerivative · entry 2 SARGEN GREGORY · CIK 0001227835 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 21:22 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 7,500 | $12.46 | $93,450.00 |
DisclosureSEC source: 0001437749-16-042120 · rdgdoc.xml · nonDerivative · entry 1 SARGEN GREGORY · CIK 0001227835 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 26, 2016 Filed Oct 28, 2016 16:08 UTC | CAMBREX CORP CBM · Entity 153359 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $40.65 | $0.00 |
DisclosureSEC source: 0000820081-16-000062 · edgar.xml · derivative · entry 1 SARGEN GREGORY · CIK 0001227835 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2023-10-26 F1 · derivative.exercise_date: The option, representing a right to purchase a total of 30,000 shares, becomes exercisable in four equal installments beginning on October 26, 2017, which is the first anniversary of the date on which the option was granted. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.